WE CLAIM:

- wherein said method comprises administering RPE cells in an amount effective to create an immunologically privileged 5 site.
- A method of treating a disease in a mammal wherein said method comprises administering RPE cells that supply a therapeutic protein or biologically active molecule to a 10 mammal in need of said treatment, wherein said RPE cells are administered in an amount effective to create an immunologically privileged site and sustain a therapeutic effect.
- A method of treating a disease in a mammal wherein said method comprises co-administering of RPE cells with cells that supply a therapeutic protein or other biologically active molecule, wherein said RPE cells are administered in an amount effective to create an immunologically privileged site and cells that supply a therapeutic protein or other biologically active molecule are administered in an amount effective to sustain a therapeutic effect.
- 4. The method of Claim 2 or 3 wherein said therapeutic 25 protein or other biologically active molecule consist of a growth factor, cytokine, hormone, peptide fragment of a hormone, inhibitor of cytokines, peptide growth or differentiation factor, interleukin, chemokine, interferon, neurotransmitter, colony stimulating factor or angiogenic 30 factor.
- 5. The method of Claim 3 wherein said cells that produce said therapeutic molecule are cells transformed by a nucleic acid encoding said therapeutic protein or other 35 piologically active molecule.

Sur

6. The method of Claim 1, 2 or 3 wherein the RPE cells, or the co-administered cells, are attached to a matrix prior to administration.

0

7. The method of Claim $\frac{1}{2}$ or 3 wherein said administering is by transplantation.

8

8. The method of Claim 2 wherein the RPE cells are transformed by a nucleic acid encoding said therapeutic protein or other biologically active molecule.

L

9. The method of Claim $\frac{1}{1}$ or 3 wherein said RPE cells are administered in a dose ranging from 10^3 to 10^7 cells.

15

10. The method of Claim 3 wherein said cells that produce said biological factor are administered in a dosage of from 103 to 107 cells.

2

20 11. The method of Claim 7 wherein said transplantation is by xenograft.

12. The method of Claim / wherein said transplantation is by allograft.

25

13. The method of Claim 2 or 3 wherein the disease consists of a neurological, cardiac, endocrine, hepatic, pulmonary, metabolic or immunological disease.

0

30 14. The method of Claim 1/2 or 3 wherein the RPE cells are re-administered in an effective amount to sustain an immunologically privilege site.

Lyby C3 15. The method of Claim 2 or 3 wherein the RPE cells,

35 or co-administered cells that supply the therapeutic protein or other biologically active molecule are re-administered in an effective amount to sustain a therapeutic effect.

A pharmaceutical composition comprising RPE cells and cells that produce a therapeutic protein or other biologically active molecule and a pharmaceutically acceptable carrier.

> A pharmaceutical composition comprising RPE cells attached to a matrix.

A pharmaceutical composition comprising RPE cells 10 and cells that produce a therapeutic protein, or other biologically active molecule, are attached to a matrix.


The composition of Claim 16 wherein therapeutic protein, or other biologically active molecule consists of a 15 growth factor, cytokine, hormone, peptide fragment of a hormone, inhibitor of cytokines, peptide growth or differentiation factor, interleukin, chemokine, interferon, colony stimulating factor or angiogenic factor.

26. A pharmaceutical composition comprising RPE cells 20 and a pharmaceutically (acceptable carrier.

A compartmentalized kit adapted to receive a first container adapted to contain RPE cells and a second container (25 adapted to contain cells that produce a therapeutic molecule that is absent or defective in a disease.

A compartmentalized kit adapted to receive a first container adapted to contain RPE cells and a second container 30/adapted to contain pancreatic islet of Langerhans cells.

23/ An article of manufacture comprising a packaging material and RPE cells contained within said packaging material, wherein said RPE cells are effective for creating 35 an immunologically privileged site in a mammal, and wherein said packaging material contains a label that indicates that



24. A method for producing Fas L comprising (i)
5 culturing RPE cells which express the Fas L; and (ii)
recovering the Fas L from the cell culture.

10

add Ma

 \mathcal{D}'

15



20

25

30

35